Research Projects

As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all related to psychological distress and anxiety, are significant drivers of reduced quality of life in older adults. This project builds on evidence that...

The number of people with Alzheimer’s disorder (AD) and other dementia is expected to triple worldwide by 2050. To tackle the global burden of AD, the European Parliament acknowledges and points to the urgent need to develop interventions that can prevent or delay AD. The locus coeruleus (LC) in the brainstem plays a key role in determining late...

Every year, Alzheimer's disease (AD) affects about 800,000 new patients in Europe and directly causes 50% of dependency of aged persons. Currently there is no test to diagnose this disease. There is a great need to improve outcomes for patients with lung cancer which causes between 15-28% of all cancer deaths in Europe. Chemical and structural...

The long-term goal of this project is to understand how neuronal assemblies exchange information (functional or neuronal communication), and how variability in neuronal communication explains variability in behavioural performance, both in the intact and injured brain. Communication involves temporal interactions between neuronal assemblies either...

MEMOSAD aims at defining the molecular mechanisms of Abeta- and Tau-induced synaptotoxicity and at developing disease-modifying therapeutics for the prevention of memory loss in Alzheimer disease (AD). Insoluble aggregates of the two proteins provide the pathological hallmarks of this incurable brain disorder. Early stage AD is characterized by a...

In M-GATE, ESRs will combine state-of-the art experimental neurophysiology, innovative technologies, and advanced theoretical approaches to unveil memory mechanisms, from single neurons to brain networks, to cognition and behaviour, addressing the healthy and diseased brain. Through research and training from top-class scientists and close...

Microglia are the resident immune cells of the brain, display extensive heterogeneity, and contribute to a wide range of cellular processes in both homeostasis and disease. They play a major role in the pathogenesis of Alzheimer’s disease (AD), the leading cause of dementia and a major cause of mortality worldwide. Microglia closely interact with...

Microglia are immune cells that monitor our brain and degrade unhealthy neurons and excess synapses. In Alzheimer’s disease (AD) however, microglia excessively destroy synapses, marking them as enticing treatment targets. AD patients accumulate cortical Amyloid-beta (Aβ) plaques and neurofibrillary tau tangles, whilst losing neurons and synapses...

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where...

Dementia researchers are increasingly focusing their efforts on finding ways to prevent the onset of dementia symptoms in the first place, and for this they need to work with people who are still in the very earliest stages of the disease. The MOPEAD project aims to identify and test different models for engaging with this important group and...

Dementia is currently diagnosed largely based on cognitive decline, while pathology starts years before symptom onset. To make progress in the development of effective drugs for dementia, there is an urgent need for biomarkers to enable precision health: for early and specific diagnosis and objective monitoring of disease progression. With its...

The search for effective therapies and early detection strategies for Alzheimer’s Disease (AD), the major cause of dementia in Europe, is imperative. It is known that β-amyloid (Aβ) peptide plays a central role in neurodegeneration. In AD brain, Aβ is released in a soluble form that progressively becomes insoluble forming aggregates; extracellular...